Close menu




June 4th, 2024 | 07:00 CEST

Canopy Growth, Vidac Pharma, BioNTech - Opportunities after the correction

  • Biotechnology
  • Pharma
Photo credits: pixabay.com

After record highs for the DAX, Dow Jones, and the precious metal gold, the stock market has been burdened by a broad correction in recent days, which could spread further in the coming weeks. However, the setback offers many investors the opportunity to pick up their favorites once again at discounted levels. In addition to the highly volatile cannabis stocks, there are enormous opportunities in the biotech sector, where takeovers are on the rise.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: CANOPY GROWTH | CA1380351009 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Canopy Growth - Little momentum

    The rocket-like rise of 450% within 6 weeks in mid-March was followed by an equally sharp sell-off to the current price of CAD 11.99. With the announcement of the figures for the fourth quarter and the financial year, investors were hoping for a turn for the better and a continuation of the interim rally.

    However, one of the leading companies in the cannabis sector, which focuses on the development, production and distribution of cannabis products for medical and recreational purposes, failed to provide any impetus. The shares lost more than 15% week-on-week and are about to test their prominent horizontal resistance at CAD 11.19. A break is likely to take the volatile share into the single-digit price range for the time being.

    The company from Smiths Falls in Ontario reported a significantly lower loss of minus CAD 1.03 per share in the final quarter of the financial year compared with minus CAD 14.27 in the same period of the previous year. However, this meant that Canopy Growth fell short of analyst forecasts, which assumed a loss of only minus CAD 0.443.

    With a loss per share of CAD 8.79, the Canadians also fell short of analyst estimates for the year as a whole, who had predicted a loss of just CAD 6.766 per share.

    Vidac Pharma - Stepping on the gas

    The wave of takeovers in the biotech sector continues unabated. One candidate for an acquisition could be the biopharmaceutical company Vidac Pharma, which is valued at just EUR 8.88 million. The reasons for this are apparent, as the Company is pioneering a new class of cancer treatments. Vidac Pharma owns 7 patent families. Their strategy is to transform the tumor's microenvironment in order to kill it without damaging the surrounding normal tissue.

    Vidac Pharma's focus here is on its lead product, VDA-1102, which is designed to combat a cancerous disease of the white blood cells known as lymphocytes. The drug candidate has already received approval for the second phase of clinical Phase 2a, which has a duration of 3 to 4 months. Promising results were already reported at the beginning of the year based on 50% of the test subjects. The study phase is expected to last between 3 and 4 months, and the innovator led by Prof. Max Herzberg expects final results before the end of this financial year.

    In addition to VDA-1102, another promising candidate from Vidac Pharma is making positive headlines. With their latest cancer therapeutic candidate, VDA-1275, the Company has advanced another hot prospect into the next phase of preclinical drug studies. The drug has shown strong synergistic effects in combination with standard therapy for solid tumors in various laboratory trials.

    Vidac Pharma's shares, which are listed in Stuttgart and Hamburg, have so far received little attention from the broader stock market audience. However, if the positive study results continue, this situation will likely change quickly. Interested investors should, however, strictly limit their exposure to the stock.

    BioNTech - Upward trend ended?

    The chart of the former stock market star has been on a recovery course since the low on March 20, when the Mainz-based biotech company announced disappointing annual figures with drastic declines in revenue and earnings. After hitting a low for the year of USD 85.21, BioNTech shares briefly broke above both the upward trend that has been in place since August 2023 and the 200 EMA, currently at USD 99.82, last week, but then bounced off the resistances amid high volumes. If this area is sustainably overcome, the next price target would be USD 117.40, the high for the year to date. The share must decisively defend the level of its yearly low as it moves southward.

    The report published at the weekend could provide positive impetus. Accordingly, partners BioNTech and the Danish biotech company Genmab A/S presented initial data from an ongoing Phase 2 trial (NCT05117242) with the biospecific antibody investigational drug Acasunlimab (DuoBody-PD-L1x4-1BB) at the American Society of Clinical Oncology ("ASCO") 2024 Annual Meeting, which is taking place from May 31 to June 4, 2024 in Chicago, IL.

    The study will evaluate the candidate BNT311 (GEN1046), both as monotherapy and in combination with pembrolizumab, in patients with PD-L1-positive metastatic non-small cell lung cancer whose disease has progressed after one or more prior anti-PD-L1 lines of therapy. At the end of the observation period, data showed a 12-month overall survival rate of 69%, a median overall survival of 17.5 months and an overall response rate of 30% (confirmed ORR 17%) in the cohort treated every six weeks with a combination of acasunlimab and pembrolizumab.

    "The results of this ongoing Phase 2 study are encouraging. The initial results of treatment with acasunlimab in combination with pembrolizumab administered every six weeks suggest a potentially significant effect in patients with metastatic non-small cell lung cancer," said Judith Klimovsky, Executive Vice President and Chief Development Officer at Genmab.


    BioNTech failed in its initial attempt to break the medium-term downtrend. The cannabis company Canopy Growth was unable to provide any positive impetus for its shares when it published its figures for the 2024 financial year. Vidac Pharma is advancing its preclinical studies with cancer metabolism inhibitor VDA-1275 and could come into the spotlight of Big Pharma.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

    Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

    • Biotechnology
    • Pharma

    In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?

    Read

    Commented by André Will-Laudien on June 10th, 2024 | 06:45 CEST

    Nasdaq short bets remain dangerous! TUI, Saturn Oil + Gas, Plug Power, and Evotec in the crosshairs

    • Mining
    • Oil
    • renewableenergies
    • Travel
    • Biotechnology

    Last week, Nvidia shares gave the bears a scare. Despite massive price gains in recent months, the shares of the specialist for high-performance chips gained another 20%, adding USD 600 billion to its valuation. Now, behind Microsoft, Nvidia is the second most valuable company in the world, surpassing even Apple. Of course, this did not happen without reason because, as of today, the share is trading at 1:10, which means a tenfold increase in the number of shares in the portfolio for shareholders. This does not change the market value per se, as the share price is also reduced by 90% at the opening. The aim is to make the share more accessible and allow retail investors to get involved. Stock splits of this kind are common on the NASDAQ and have often brought investors additional price gains in the following months. Where are the opportunities for investors?

    Read

    Commented by André Will-Laudien on June 6th, 2024 | 07:00 CEST

    Rally start for biotech! Evotec, Bayer, Defence Therapeutics, CureVac and BioNTech in pole position

    • Biotechnology
    • Pharma

    Sell in May and go Away! Far from it, as the stock markets continue to rise steadily in June. After a disappointing start to the year, the biotech sector is now also showing signs of recovery. Bayer and Evotec seem to have found their footing with improved outlooks. BioNTech, CureVac and Defence Therapeutics are providing promising data on various cancer vaccines. Whoever opens the door here can save millions of lives. And investors stand to make a fortune if one of the vaccines hits the mark. We analyze the opportunities and risks.

    Read